[{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||APC receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"||CD37","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Zhejiang Doer Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"DR30303","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SLOVENIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"HPV Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Nonavalent Hpv Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Nouscom AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MVA-209-FSP","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||VISTA","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by MSD Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : HPV Vaccine is a Vaccine drug candidate, which is currently being evaluated in clinical studies for the treatment of Uterine Cervical Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          May 29, 2025

                          Lead Product(s) : HPV Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : University Medical Centre Ljubljana

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Keytruda (Pembrolizumab) is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Keytruda

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          April 30, 2025

                          Lead Product(s) : Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Rabin Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Nonavalent Hpv Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Papillomavirus Infections.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Nonavalent Hpv Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Recipient : Fundación Huésped

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present ...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 05, 2023

                          Lead Product(s) : NOUS-209,MVA-209-FSP,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Nouscom AG

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemoth...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          December 26, 2022

                          Lead Product(s) : ATG-037,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Antengene

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is i...

                          Product Name : Lynparza

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 21, 2022

                          Lead Product(s) : Olaparib,Abiraterone Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          December 15, 2022

                          Lead Product(s) : DR30303,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Zhejiang Doer Biologics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.

                          Product Name : Lynparza

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 15, 2022

                          Lead Product(s) : Olaparib,Abiraterone Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : AstraZeneca

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          December 12, 2022

                          Lead Product(s) : PMC-309,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : PharmAbcine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 06, 2022

                          Lead Product(s) : VB10.16,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Nykode Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank